Lexington, KY, Aug 19, 2016 -- The Vascular Interventional Advances (“VIVA”) awarded one of its highest honor, the Leader In EndoVascular Education Award (“LIVE Award”), to Dr. Mark C. Bates of Nexeon MedSystems (“Nexeon” or “the Company”) with plans for presentation at the VIVA General Session in September of this year. The VIVA LIVE Award recognizes vascular specialists who have devoted a considerable portion of their professional careers to education students, post-graduate trainees, and peers in all aspects of interventional cardiology.
“Our team is very fortunate to have [Dr. Bates’] experience and knowledge at the forefront of our development program,” said Nexeon CEO Will Rosellini. “Dr. Bates has a consistent track record of solving unmet clinical needs with innovation; he has either created the science from scratch or found early on potential in existing inventions. He has incredible inertia to push what’s valuable through the gauntlet of medtech R&D and commercialization to get these solutions in the hands of physicians and to help as many patients.”
Rosellini indicated that the Company has a portfolio of intellectual property in various stages of development ranging from early prototyping to ongoing clinical trials. The Company is focused on the use of bioelectronics to deliver next generation medical care and is growing its research and commercialization teams infrastructure in Lexington, KY, to support the onboarding and launch of these products. Current efforts are being devoted to active implantable product development including implantable neuromodulation systems and photo-activated drug delivery systems.
About Nexeon MedSystems: Nexeon MedSystems was founded in 2005 by super-innovator, interventional cardiologist Dr. Mark C. Bates of West Virginia. Dr. Bates is attributed to innovation of over 60+ US and international patents, and over the past decade, Nexeon has experienced several exits and product launches. In early 2016, Nexeon completed a merger with medtech incubator Rosellini Scientific, which brought with it a pipeline of preclinical and clinical projects supported with non-dilutive funding as well as holdings in seven existing medtech startup companies. Nexeon has since moved its corporate headquarters to Lexington, Kentucky, and plans to continue the development and manufacturing of its portfolio of medical device products.
Forward-Looking and Cautionary Statements: Statements in this press release that are not strictly historical may be “forward-looking” statements, which involve risks and uncertainties, and Nexeon undertakes no obligation to update any such statements to reflect later developments. These risks and uncertainties include Nexeon’s ability to successfully complete on the terms and conditions contemplated, and the financial impact of, its strategic portfolio repositioning actions, as well as economic and currency conditions, market demand, pricing, protection of intellectual property, and competitive and technological factors, among others, as set forth in Nexeon’s subsequent reports filed with the SEC.